D. E. Shaw & Co. Inc. Trims Position in Haemonetics Co. (NYSE:HAE)

D. E. Shaw & Co. Inc. cut its stake in Haemonetics Co. (NYSE:HAE) by 99.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 18,237 shares of the medical instruments supplier’s stock after selling 3,281,763 shares during the period. D. E. Shaw & Co. Inc.’s holdings in Haemonetics were worth $1,424,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in HAE. Crestline Management LP raised its stake in shares of Haemonetics by 14.8% during the fourth quarter. Crestline Management LP now owns 5,801 shares of the medical instruments supplier’s stock valued at $453,000 after purchasing an additional 747 shares during the period. Brevan Howard Capital Management LP increased its stake in Haemonetics by 404.3% during the fourth quarter. Brevan Howard Capital Management LP now owns 24,810 shares of the medical instruments supplier’s stock valued at $1,937,000 after purchasing an additional 19,890 shares during the last quarter. Bridgefront Capital LLC acquired a new position in shares of Haemonetics in the 4th quarter valued at about $395,000. Captrust Financial Advisors grew its position in shares of Haemonetics by 14.7% during the 4th quarter. Captrust Financial Advisors now owns 4,872 shares of the medical instruments supplier’s stock valued at $380,000 after buying an additional 624 shares during the last quarter. Finally, Balyasny Asset Management L.P. bought a new stake in shares of Haemonetics during the 4th quarter valued at about $3,845,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

Haemonetics Price Performance

Shares of NYSE:HAE opened at $66.15 on Friday. The company has a market capitalization of $3.32 billion, a PE ratio of 26.04, a price-to-earnings-growth ratio of 1.11 and a beta of 0.32. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.55 and a current ratio of 3.97. The stock has a fifty day moving average of $63.10 and a 200-day moving average of $71.10. Haemonetics Co. has a one year low of $55.30 and a one year high of $94.99.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share for the quarter, beating analysts’ consensus estimates of $1.22 by $0.02. The business had revenue of $330.60 million during the quarter, compared to analyst estimates of $329.38 million. Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. Haemonetics’s revenue for the quarter was down 3.5% on a year-over-year basis. During the same quarter last year, the company posted $0.90 EPS. As a group, equities analysts anticipate that Haemonetics Co. will post 4.55 EPS for the current fiscal year.

Wall Street Analyst Weigh In

HAE has been the subject of a number of research reports. Raymond James restated a “strong-buy” rating and issued a $105.00 target price (down from $115.00) on shares of Haemonetics in a research note on Friday, May 9th. Needham & Company LLC lowered their price objective on Haemonetics from $104.00 to $84.00 and set a “buy” rating for the company in a research note on Thursday, May 8th. Bank of America cut shares of Haemonetics from a “neutral” rating to an “underperform” rating and decreased their target price for the stock from $95.00 to $68.00 in a research report on Friday, February 7th. Barrington Research dropped their price target on shares of Haemonetics from $108.00 to $95.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. Finally, JMP Securities reiterated a “market outperform” rating and set a $100.00 price objective on shares of Haemonetics in a research report on Tuesday. One analyst has rated the stock with a sell rating, two have given a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $97.89.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.